We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Edwards Lifesciences Corp (EW) Com Stk USD1

Sell:$94.68 Buy:$94.76 Change: $1.20 (1.25%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $1.20 (1.25%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $1.20 (1.25%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including Edwards SAPIEN XT, the Edwards SAPIEN 3, and the Edwards SAPIEN 3 Ultra transcatheter aortic heart valves are used to treat heart valve disease.

Contact details

1 Edwards Way, ONE EDWARDS WAY
United States
+1 (949) 2502500

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$58.90 billion
Shares in issue:
621.75 million
Health Care Equipment
New York Stock Exchange
United States
US dollar

Key personnel

  • Michael Mussallem
    Chairman of the Board, Chief Executive Officer
  • Scott Ullem
    Chief Financial Officer, Corporate Vice President
  • Jean-Luc Lemercier
    Corporate Vice President - EMEA (Europe, Middle East and Africa)
  • Donald Bobo
    Corporate Vice President - Strategy and Corporate Development
  • Daveen Chopra
    Corporate Vice President - Surgical Structural Heart
  • Catherine Szyman
    Corporate Vice President - Critical Care
  • Huimin Wang
    Corporate Vice President - Japan, Asia and Pacific
  • Larry Wood
    Corporate Vice President - Transcatheter Aortic Valve Replacement

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.